# Pizarra — PT-pseudo_376de00c8131 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_376de00c8131
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 8.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.09 ng/mL²
  - PSA velocity: 0.65 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 98.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.61692226 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Latex
  - Additional notes: PSA 8.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 98 mL. csPCa 0.62.

Vitals: weight 109 kg, height 192 cm, BMI 29.6, BP 122/78 mmHg, HR 68 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2013).

Chief complaint: Persistent elevation in prostate-specific antigen accompanied by a newly identified PI-RADS 4 lesion on magnetic resonance imaging, documented after a prior negative biopsy.

History: At 52 years of age, he works as a retired secondary school teacher. Initial evaluation in late 2022 focused on a prostate-specific antigen level of 7.1 ng/mL, which led to a systematic biopsy yielding entirely benign results. He is married and maintains an independent household, with his adult son living close by. Physical activity includes cycling roughly 20 kilometres two times each week, while alcohol intake averages 10 units weekly. Lower urinary tract symptoms remain negligible, reflected by an International Prostate Symptom Score of 2 out of 35. He reports no haematuria, pelvic discomfort, or systemic complaints. A 13 pack-year smoking history was concluded in 2013, and he has no known drug allergies beyond latex. Recent routine dental visits continue, and he relies on large-print materials for correspondence due to mild visual impairment. No other significant surgical history or comorbidities are noted, and he takes no active medications.

Physical examination: DRE — texture: smooth and firm; mobility: normal; asymmetry: absent. The prostate presents as symmetrically enlarged without palpable nodules. General inspection reveals a well-nourished individual ambulating independently. Vital signs remain stable, and there is no evidence of abdominal masses or peripheral lymphadenopathy.

Patient info: retired secondary school teacher; Married; Lives alone; adult son nearby.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 10 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.82 +/- 0.10   (95% CI 0.61-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.68 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence to change the biopsy recommendation?
  - previous_notes (get_previous_notes) -> What was the prior management context and agreement with the patient?

This case hinges on whether the PI-RADS 4 finding on MRI, combined with the prior negative biopsy, mandates a re-biopsy according to protocol, which requires reviewing the imaging, PSA trajectory, and prior management.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific numerical values of PSA (8.8 ng/mL), PSA density (0.09 ng/mL²), PSA velocity (0.65 ng/mL/yr), and the PI-RADS 4 score, which are critical for risk stratification.
The prior did not account for the conflict between the high csPCa probability (0.61692226) and the benign DRE finding, nor did it weigh the specific context of a prior negative biopsy against the current PI-RADS 4 finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a high probability (0.82), but the guideline track record suggests that the decision hinges on specific retrieved data. The prior failed to account for the potential for the PI-RADS 4 finding to be a strong indicator for re-biopsy, which the protocol explicitly requires checking. The high aleatoric uncertainty (H=0.68) suggests the model struggles with the data distribution, meaning the suggestion might be based on a subset of data that doesn't apply here.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Does the PSA trend provide evidence to change the biopsy recommendation?
previous_notes - What was the prior management context and agreement with the patient?
laboratory panel - What are the full laboratory results, specifically for PSA density and other markers?

GUIDELINE ANCHOR
The guideline states that a PI-RADS 4-5 lesion mandates a repeat biopsy to confirm histological progression before changing treatment strategy.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm. PSAD 0.09 ng/mL/mL. csPCa predicted probability 0.61692226.
get_psa_trend
PSA trend: [{"date": "Nov 2022", "val": 7.3}, {"date": "Aug 2023", "val": 7.3}, {"date": "May 2024", "val": 6.5}, {"date": "Feb 2025", "val": 8.8}]
get_previous_notes
Previous notes: 07 Sep 2023 - Dr. N. Kuiper (GP): Routine screening captured a PSA level of 6.4 ng/mL, marking a modest decrease from the 7.1 ng/mL recorded in late 2022. Owing to the sustained elevation beyond standard limits and his age, his records were submitted to the urology outpatient clinic to facilitate further diagnostic evaluation and potential imaging. 05 Mar 2024 - Dr. N. Kuiper (GP): Serial testing indicates a gradual PSA ascent, currently at 7.0 ng/mL. Having finished his initial urological workup, he returned for review. In light of the persistent biochemical markers and the requirement for structured surveillance, a follow-up appointment has been arranged to evaluate the most recent imaging and clinical findings.

NOT RETRIEVED
laboratory_results
Laboratory results: Left closed because the moderator's agenda did not explicitly ask for the full panel, only for specific information related to PSA density, infection, or renal function before an invasive procedure.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm.
- PSA trend: PSA velocity is positive, with a rise from 6.5 ng/mL (May 2024) to 8.8 ng/mL (Feb 2025).
- Guideline Criterion: Re-biopsy is indicated for a PI-RADS 4-5 lesion following a prior negative biopsy.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative.
- Physical exam: DRE findings are Normal.

WHERE THIS LEANS
The evidence strongly supports a biopsy based on the PI-RADS 4 finding and the positive PSA trend, aligning with the expert protocol.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 4 finding on MRI and the positive PSA trend, strongly supports the guideline criterion for re-biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is supported by convergence across all inputs. The guideline criterion mandates re-biopsy for a PI-RADS 4-5 lesion following a prior negative biopsy. This was strongly supported by the retrieved MRI report showing a PI-RADS 4 lesion, combined with the positive PSA trend showing a rise from 6.5 ng/mL to 8.8 ng/mL. The statistical prior also suggested biopsy, and the evidence confirmed the protocol's recommendation.

Variables that carried weight: bx=important, age=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
